GnuBIO, Inc.

GnuBIO, Inc. specializes in innovative desktop DNA sequencing solutions that streamline genomic analysis, catering to research and clinical laboratories. Their platform integrates essential sequencing functions into a single, user-friendly system. GnuBIO, Inc.

is focused on providing advanced desktop DNA sequencing technology that encompasses all essential aspects of DNA sequencing. The company was acquired by Bio-Rad Laboratories, Inc. in April 2014, with financial terms undisclosed. The headquarters of GnuBIO is located in Cambridge, US.

The company was founded by individuals with a background in biotechnology, though specific founder details are not available. GnuBIO has successfully raised a total of USD 10. 00 mn through its funding rounds, including a Series B round amounting to USD 10. 00 mn, which was finalized in 2014.

GnuBIO's primary offering is its innovative desktop DNA sequencing platform, designed to integrate all essential functions of DNA sequencing into a single, cohesive system. This platform streamlines the entire workflow, encompassing target selection, DNA amplification, sequencing, and analysis within a low-cost instrument. Utilizing emulsion microfluidics technology, the sequencer operates within tiny aqueous drops, making it suitable for a range of applications from single gene analysis to whole genome sequencing. GnuBIO's technology appeals to a diverse client base, including research and clinical laboratories that seek rapid genomic results.

The platform has been designed to cater to users worldwide, with particular emphasis on markets in North America and Europe, where the demand for efficient and integrated sequencing processes is growing. GnuBIO generates revenue through the sale of its fully integrated DNA sequencing platforms and associated consumables. Transactions typically occur through direct sales to research institutions and clinical laboratories, where clients purchase the sequencing instruments along with necessary consumables to ensure ongoing operation. The company offers a streamlined purchasing process, allowing users to simply load genomic DNA into the instrument's cartridge, initiate the sequencing process, and receive results within hours.

Pricing structures are associated with the flagship sequencing platform, which includes a single user interface for ease of operation. The combination of instrument sales and recurring consumable purchases creates a sustainable revenue model, enhancing GnuBIO's financial stability and market presence. With the acquisition by Bio-Rad Laboratories, GnuBIO is positioned for further growth and expansion. The company is expected to leverage Bio-Rad's resources to enhance its product offerings and expand into new geographical markets, particularly focusing on Europe and Asia by 2016.

Recent funding from the Series B round will be utilized to support the development of new products that aim to enhance the efficiency of genomic research processes.